SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Medical Oncology Consultation — Audre Lorde

PatientAudre Lorde
Date of birth1981-02-18
IdentifiersMRN HR-ML016-SYN; SSN (made up) 000-16-2937
Document date2026-03-30
AuthorBeatriz Lozano, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Woman of 45, five and a half months after right total mastectomy for stage IA hormone receptor-positive, HER2-negative breast cancer, on tamoxifen since one month after surgery and now moving her survivorship care to primary care at this center. Please review the adjuvant endocrine plan and advise on hot flashes, surveillance, and genetic assessment, so that we can share her follow-up. [S]

Urgency: Routine, within four weeks. [S]

Questions for the consultant:

History of Present Illness

Ms. Lorde is seen at the request of Dr. Fairweather to share her survivorship care. She found a right breast lump at self-examination last September; a core biopsy showed invasive ductal carcinoma, and she had a right total mastectomy with flat closure and sentinel node biopsy at the end of September. She chose not to have reconstruction or wear a prosthesis, and this is respected. She has taken tamoxifen 20 mg daily for five months with three or four hot flashes a day, no abnormal vaginal bleeding, and no leg swelling or breathlessness. Her periods are regular. She has no bone pain, cough, headaches, abdominal pain, or new lumps. She walks and writes daily. She asked for the reasoning behind each recommendation. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route2025-10-27activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1978 breast cancer and mastectomyactiveconfirmed C50.411S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesisactiveconfirmed Z90.11S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own.
Long-term use of tamoxifen as adjuvant endocrine therapyactiveconfirmed Z79.810S — Synthetic treatment status.

Physical Exam

Vital signs recorded on 2026-03-30; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralWell
Breasts and chest wallRight chest wall flat, scar healed, no nodules; left breast without masses
Lymph nodesNo axillary, supraclavicular, or cervical nodes
ExtremitiesNo arm swelling; calves soft and non-tender
AbdomenSoft; liver not enlarged

Assessment

Data reviewed: Outside diagnostic mammogram and ultrasound reports; core biopsy and mastectomy pathology with ER, PR, HER2, and Ki-67; sentinel node pathology (0 of 2); the 21-gene recurrence score of 14; her medication list; and the PHQ-9 and GAD-7 from Dr. Fairweather's visit three weeks ago. [S]

Plan of Treatment